🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in France / NCT06861036
Starting soon Not applicable

Heterogeneity of Oral Squamous Cell Carcinoma Analysis by Single Cell RNA Sequencing

NCT06861036 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-05-15
Last updated
2025-03-06

Condition(s) studied

Oral Squamous Cell Carcinomas

Investigational drug(s) / intervention(s)

BiospecimenBlood sampling

Biospecimen: * 1 or 2 tumoral specimen (depending on the size of the tumor) * 1 specimen of the healthy oral mucosa * 1 leucoplakia specimen if applicable. The biospecimens will be collected at the time of the surgery organised for the standard routine medical care.

Blood sampling: Blood sampling (6 mL), taken from a routine biological exam.

Study summary

The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and leucoplasic) counterparts by scRNAseq in OSCC patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * I1. Male or female at least 18 years old. * I2. Patient with OSCC and undergoing surgery at the Centre Léon Bérard. * I3. Patient who has agreed to participate in this research and sign consent. * I4. Patient affiliated to a medical insurance. Exclusion Criteria: * NI1. Pregnant or nursing woman. * NI2. Contraindication to general anesthesia. * NI3. Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...). * NI4. Patient under curatorial or guardianship or placed under the protection of justice.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Léon Bérard Lyon France

More Centre Leon Berard trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06861036 on ClinicalTrials.gov ↗ ← All trials in France